文献速递糖尿病肥胖与代谢综合征

2型糖尿病诊断后早期体重下降、糖尿病缓解及长期轨迹:一项回顾性研究

Early weight loss, diabetes remission and long-term trajectory after diagnosis of type 2 diabetes: a retrospective study.
PubMed 文献 · Diabetologia · 2025-03-22

该回顾性研究分析两个新诊断2型糖尿病队列(队列1 n=1934,随访至25年;队列2 n=13277,随访至10年)。体重下降≥10%与糖化血红蛋白持续降低及缓解率升高相关(队列1:20.2% vs 5.5%,HR 4.2),但与并发症发生率降低无关;缓解本身与新发微血管病变风险降低独立相关(校正HR 0.84)。

要点

  • 新诊断2型糖尿病患者中,早期体重下降≥10%与糖化血红蛋白持续改善及缓解率升高3至4倍相关。
  • 体重下降≥10%与并发症发生率降低无关,而缓解与微血管病变风险降低独立相关。
  • 体重下降5%至<10%对糖化血红蛋白、血脂及缓解率的改善有限,且不及体重下降≥10%。

核心结论

  • 2型糖尿病早期体重下降≥10%与血糖持续改善及缓解率升高3至4倍相关。
  • 缓解本身较体重下降更与并发症风险降低相关。

研究设计与样本

  • 回顾性分析两个新诊断2型糖尿病队列;队列1纳入1934人,随访至25年;队列2纳入13277人,随访至10年。
  • 按是否体重下降≥10%分为两组;敏感性分析另设体重下降5%至<10%组。

主要发现

  • 队列1中体重下降≥10%者占15.9%(n=308),队列2中占8.8%(n=1167)。
  • 队列1中体重下降≥10%与糖化血红蛋白持续降低相关(平均差值2.1 mmol/mol;0.19%),缓解率高于体重下降<10%组(20.2% vs 5.5%;HR 4.2)。
  • 队列2中体重下降≥10%组与<10%组缓解率分别为13.2%和4.1%(HR 2.6)。
  • 队列1中,以体重下降<5%为参照,缓解的HR在体重下降≥10%组为5.2,在体重下降5%至<10%组为1.7。
  • 体重下降≥10%与并发症发生率降低无关;缓解与新发微血管病变风险降低独立相关(校正HR 0.84;95% CI 0.73,0.97;p=0.019)。

关键数值与推荐

  • 体重下降≥10%组与<10%组比较:队列1缓解率20.2% vs 5.5%(HR 4.2),队列2缓解率13.2% vs 4.1%(HR 2.6)。
  • 以体重下降<5%为参照,体重下降≥10%组缓解HR 5.2,体重下降5%至<10%组缓解HR 1.7。
  • 缓解与新发微血管病变风险降低独立相关:校正HR 0.84;95% CI 0.73,0.97;p=0.019。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Weight loss can improve glycaemic management in individuals with type 2 diabetes, but its long-term effects on remission, cardiovascular risk factors and complications remain unclear. We investigated clinical outcomes following non-interventional ≥10% body weight loss in people with newly diagnosed type 2 diabetes in a routine care setting. METHODS: We retrospectively analysed two cohorts of people with newly diagnosed type 2 diabetes. After exclusions, cohort 1 included 1934 individuals followed for up to 25 years; cohort 2 comprised 13,277 individuals followed for up to 10 years. Participants were categorised into two groups based on whether or not they lost at least 10% body weight. In a sensitivity analysis, a group of participants with intermediate weight loss (5% to <10%) was also considered. Outcomes included HbA1c, diabetes remission, cardiovascular parameters and chronic complications. RESULTS: Participants (58% male) had a mean age of 62 years and a mean diabetes duration of <2 years at inclusion; mean baseline HbA1c was 57-64 mmol/mol (7.4-8.0%) and mean BMI was ~30 kg/m2. Weight loss ≥10% was obtained in 15.9% (n=308) of participants in cohort 1 and in 8.8% (n=1167) in cohort 2. In cohort 1, weight loss ≥10% was associated with a sustained reduction in HbA1c (mean difference 2.1 mmol/mol; 0.19%) and a higher remission rate than in the <10% weight loss group (20.2% vs 5.5%; HR 4.2). These findings were confirmed in cohort 2, with remission rates of 13.2% and 4.1% (HR 2.6) in the ≥10% and <10% weight loss groups, respectively. Weight loss ≥10% improved systolic BP and HDL-cholesterol and triglyceride levels. Participants with weight loss of 5% to <10% (28.2% in cohort 1 and 17.4% in cohort 2) had marginal improvements in HbA1c, lipids and remission rates compared with participants with weight loss <5%, and such results were inferior to those achieved with weight loss ≥10%. In cohort 1, compared with weight loss <5% (reference), the HR for remission was 5.2 with weight loss ≥10% vs 1.7 with weight loss 5% to <10%. Weight loss ≥10% was not associated with a reduced incidence of complications. On the other hand, remission was independently associated with a significantly lower rate of new-onset microangiopathy (adjusted HR 0.84; 95% CI 0.73, 0.97; p=0.019). CONCLUSIONS/INTERPRETATION: Early weight loss of ≥10% in type 2 diabetes was associated with sustained glycaemic improvements, increasing by three to four times the rates of diabetes remission. Remission, in turn, more than weight loss was associated with a reduced risk of complications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Morieri ML, Rigato M, Frison V, et al. Early weight loss, diabetes remission and long-term trajectory after diagnosis of type 2 diabetes: a retrospective study. Diabetologia. 2025. PMID: 40119903. doi:10.1007/s00125-025-06402-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。